INCR Earnings Prediction
The chart below shows how INCR performed 10 days before and after its earnings report, based on data from the past quarters. Typically, INCR sees a +17.24% change in stock price 10 days leading up to the earnings, and a +19.21% change 10 days following the report. On the earnings day itself, the stock moves by +1.00%. This data can give you a slight idea of what to expect for the next quarter's release.
INCR Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
105.61M
32.50%
5.01%
Gross Margin
35.49%
-22.75%
-19.01%
Operating Margin
10.31%
-58.81%
-26.46%
Net Margin
4.99%
230.97%
-39.59%
EPS
0.19
371.43%
18.75%
No Data Available
INCR Earnings Analysis
Intercure Ltd. Corporation (INCR.O) Earnings Conference Call
Positive
Positive Point: InterCure had a successful year in 2022, achieving record revenues of $150 million with adjusted EBITDA of $32 million, demonstrating profitable growth and strong financial performance.
- Revenue growth of 77% compared to the previous year, despite a slowdown in new patient procurement in Israel during the first half of 2022.
- Gross profit increased to over $60 million, representing 41% of revenue, and adjusted EBITDA increased to $32 million, representing 22% of revenues.
- Net profits after tax were just under $70 million, generating $20 million cash flow from operations, and ending the year with $95 million cash in hand.
Positive Point: InterCure positioned itself as the largest, fastest-growing, and profitable cannabis company outside North America, showcasing strong dedication to excellence and successful execution.
- Executed well on all fronts and solidified the company's position in the cannabis market, with successful implementation of skilled professional decisions, capital investments, and strategic legal and regulatory victories.
- Maintained a leading share organically and inorganically, proving the strength of the platform and readiness for future growth opportunities.
- Successfully scaled up the upstream operations by upgrading cultivation facilities and introducing highly demanded strains, becoming the first company to meet strict new 109 protocol and resume importation.
Positive Point: InterCure expanded its vertically integrated platform, adding eight new locations to its dedicated medical cannabis pharmacy chain, and reported record revenue for the fourth quarter of 2022.
- Expanded the pharmacy chain to include 28 locations, with 20 actively dispensing medical cannabis and two international locations.
- Achieved a record fourth-quarter revenue of $41 million, reflecting increased market share, growing patient demand, and the strength of the medical cannabis dispensing operations.
Positive Point: InterCure's financial discipline and solid balance sheet position the company well for future growth and global expansion opportunities.
- Ended the year with $95 million cash in hand and a solid balance sheet, generating positive cash flow from operations of $20 million and financing about 70% of CapEx with long-term loans from Tire 1 banks in Israel.
- Positioned to continue executing profitable growth strategy, leveraging the foundation and leadership built over the years to capitalize on global expansion and consolidation opportunities.
Negative
Negative:
- Slowdown in new patient procurement in Israel during the first half of 2022 due to the loss of prescribing physicians is a concern for market growth
- Market conditions saw financially struggling companies exiting, impacting ultra-medical and legacy products
- Gross margin for the first quarter of 2022 decreased to 35%, influenced by market weakness affecting many industry players
- Adjusted EBITDA for the first quarter of 2022 slightly decreased compared to the third quarter, indicating challenges in maintaining performance amidst market dynamics
- While revenue growth was significant, the impact of struggling companies selling lower quality products at reduced prices affected the market landscape
